Bortezomib could target PSMD2, PSMB1 and PSMB5 to inhibit the proteasome degradation of cell cycle check points, to block cell proliferation and tumor growth of NSCLC, which was potential optional drug for NSCLC patients with different driven mutations or with TKI resistance. The gene discussed is PSMD2; the disease is neoplasm.